Loading...
XSTOBACTIb
Market cap119mUSD
Dec 23, Last price  
37.90SEK
1D
0.53%
1Q
-37.87%
Jan 2017
124.26%
IPO
17.70%
Name

Bactiguard Holding AB

Chart & Performance

D1W1MN
XSTO:BACTIb chart
P/E
P/S
6.51
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
1.02%
Rev. gr., 5y
6.33%
Revenues
204m
-8.75%
127,010,000117,516,0004,382,000129,005,000126,733,000109,047,000131,420,000118,736,000147,458,000150,097,000184,987,000172,315,000169,486,000223,560,000203,990,000
Net income
-138m
L+161.71%
7,669,000-24,750,000-15,305,000-38,359,000-3,407,000-95,042,000-26,501,000-26,851,000-3,251,000-14,931,00016,256,000-38,389,000-58,773,000-52,877,000-138,382,000
CFO
-52m
L
79,764,00056,714,000-2,680,000-40,916,000-45,070,000-35,743,000-20,791,000-12,411,0006,117,000-16,691,00053,982,000702,0007,256,0003,062,000-52,331,000
Earnings
Feb 06, 2025

Profile

Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally. Its infection prevention solutions reduce the risk of healthcare associated infections and the use of antibiotics. The company's products portfolio of urinary catheters, endotracheal tubes, and central venous catheters reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter and BIP Endotracheal Tube, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention. The company's products also include Bactiguard Wound Care and Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for acute, chronic, and infected wounds; surgical sutures comprise non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement used in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi. In addition, it offers ZNN Bactiguard, an orthopedic trauma implants with infection prevention technology; and Aniocyn, a wound and skin care products for dogs, cats, horses, and other pets. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.
IPO date
Jun 19, 2014
Employees
220
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
203,990
-8.75%
223,560
31.90%
169,486
-1.64%
Cost of revenue
68,978
158,925
125,181
Unusual Expense (Income)
NOPBT
135,012
64,635
44,305
NOPBT Margin
66.19%
28.91%
26.14%
Operating Taxes
(8,772)
(6,978)
(4,479)
Tax Rate
NOPAT
143,784
71,613
48,784
Net income
(138,382)
161.71%
(52,877)
-10.03%
(58,773)
53.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
228,000
BB yield
-3.94%
Debt
Debt current
190,793
10,915
9,652
Long-term debt
96,836
287,218
305,605
Deferred revenue
149,583
180,663
Other long-term liabilities
5,284
(179,265)
(180,663)
Net debt
143,708
99,096
95,996
Cash flow
Cash from operating activities
(52,331)
3,062
7,256
CAPEX
(7,189)
(10,918)
(7,294)
Cash from investing activities
(8,609)
(10,918)
(7,295)
Cash from financing activities
(11,835)
(13,892)
205,827
FCF
182,595
85,490
81,707
Balance
Cash
123,217
197,727
217,587
Long term investments
20,704
1,310
1,674
Excess cash
133,722
187,859
210,787
Stockholders' equity
(576,647)
(434,971)
(385,389)
Invested Capital
1,168,208
1,139,697
1,174,799
ROIC
12.46%
6.19%
4.56%
ROCE
22.82%
8.80%
5.56%
EV
Common stock shares outstanding
35,044
35,044
35,044
Price
61.80
-44.02%
110.40
-33.09%
165.00
15.38%
Market cap
2,165,712
-44.02%
3,868,845
-33.09%
5,782,241
20.54%
EV
2,309,420
3,967,941
5,882,078
EBITDA
174,614
113,875
91,309
EV/EBITDA
13.23
34.84
64.42
Interest
13,528
8,697
8,373
Interest/NOPBT
10.02%
13.46%
18.90%